InsiderTrades

Form 4 for CORT CORCEPT THERAPEUTICS INC

Accepted 2024-04-08 00:00:00 ET · period of report 2024-04-04 · accession 0000950170-24-042725 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2024-04-08 2024-04-04 CORT Lyon Joseph Douglas See Remarks S - Sale+OE $26.00 -5,443 7,314 -43% -$141.5K
DT 2024-04-08 2024-04-04 CORT Lyon Joseph Douglas See Remarks M - OptEx $11.35 +5,443 12.8K +74% +$61.8K
DT 2024-04-08 2024-04-04 CORT Lyon Joseph Douglas See Remarks M - OptEx $0.00 -5,443 37.2K -13% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-04-04 S D 5,443 $26.00 7,314 D — — (F3) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $26.00 to $26.01 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. (F1) Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
2 Common Common Stock 2024-04-04 M A 5,443 $11.35 12,757 D — — (F1) Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
3 Derivative Stock option (right to buy) 2024-04-04 M D 5,443 $0.00 37,224 D $11.35 · — to 2029-02-08 5,443 Common Stock (F4) Fully exercisable.